Extending the survival benefits seen with anti-HER2 agents to this expressive parcel of patients is, therefore, an attractive venue, given the poor outcomes of triple-negative BC (TNBC) patients and of endocrine-resistant, HR-positive BC patients [11,23]. This evidence concerns the gene ERBB2 and breast cancer.